June 17, 2015
Authored and Edited by Linda J. Thayer; Maureen D. Queler
The Board may soon rule on whether the Petitions for Inter Partes Review filed by the Coalition for Affordable Drugs VI, LLC (IPR2015-01092, -1096, -1102, and -1103) against certain patents owned by Celgene Corporation amount to an abuse of process deserving of sanctions. On June 9, 2015, the Board authorized Celgene to file motions for sanctions with its Patent Owner Preliminary Responses, which are due by July 30, 2015. Petitioner will have ten (10) business days to respond, and the Patent Owner five (5) business days to file a Reply. (Paper 7.)
The Coalition is an entity created by Kyle Bass, a hedge-fund manager, who claims to be targeting various patents of major pharmaceutical companies that he alleges drive up prescription drug prices. Patent Owner Celgene alleges that Mr. Bass and his business partner, Erich Spangenberg, have publicly stated that they intend to use the IPR process for the purpose of affecting the value of public companies, which Celgene alleges is an abuse of process and misuse of the IPR proceedings. By authorizing the filing of the motions for sanctions, the Board stressed that it was not deciding on the merits, but rather allowing briefing that would “facilitate development of a complete record and, thereby, will promote the just resolution of the issues raised by the Patent Owner.”
Copyright © 2015 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Webinar
Obviousness of Biologics Inventions: Strategies for Biologics Claims in the U.S., Europe, and China
May 28,2024
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.